Amphista Clears FDA Hurdle for AML Drug, Sets Clinical Trial
Event summary
- FDA cleared Amphista's IND application for AMX-883, an orally bioavailable BRD9 degrader for AML.
- Phase 1 monotherapy trial in relapsed/refractory AML and high-risk MDS to begin in H2 2026.
- AMX-883 acts independently of karyotype status, potentially benefiting a broader AML patient population.
- Company plans to explore AMX-883 combinations with venetoclax and azacitidine in early therapy lines.
The big picture
Amphista's FDA clearance marks its transition to a clinical-stage company in the competitive AML space. The focus on BRD9 degradation represents a novel approach amid growing interest in differentiation therapies for this aggressive cancer. Success could validate Amphista's proprietary Targeted Glue™ platform, potentially attracting further investment or partnership opportunities.
What we're watching
- Clinical Efficacy
- Whether AMX-883 can demonstrate meaningful efficacy in AML patients, particularly against treatment-resistant forms.
- Combination Strategy
- The pace at which Amphista advances AMX-883 into combination therapies with venetoclax and azacitidine.
- Market Differentiation
- How AMX-883's karyotype-independent mechanism positions it against emerging AML therapies.
Related topics